Ó³»­´«Ã½

Mike Gillette is a senior group leader in proteomics and biomarker discovery at the Ó³»­´«Ã½ of MIT and Harvard. He is also a pulmonary and critical care medicine attending and associate physician at the Massachusetts General Hospital, an assistant professor of medicine at Harvard Medical School, and an associate editor for Molecular & Cellular Proteomics.

Gillette has a particular interest in clinical proteomics and biomarker development. With other Ó³»­´«Ã½ colleagues, he has been involved in the development and implementation of all aspects of a coherent biomarker discovery-to-verification pipeline. With Proteomics Platform director Steve Carr, he has led Ó³»­´«Ã½ efforts in breast and ovarian cancer proteomic biomarker discovery and in molecular characterization of infectious diseases of high international health import, including pediatric febrile illness and tuberculosis.

He was an active member of the Ó³»­´«Ã½ CPTAC2 team that performed proteogenomic characterization of TCGA breast cancer specimens, and he is a co-PI on the Ó³»­´«Ã½ CPTAC3 effort focused on proteogenomic characterization of non-small cell lung cancer.

Gillette brings a blend of clinical knowledge and current practice, experimental design, mass spectrometry and diverse laboratory skills, and over fifteen years of direct experience to his leadership roles in proteomic tumor analysis and biomarker development.